| |
Thursday, February 20, 2025 | 2pm ET / 11am PT Clinical trials only continue to increase in complexity. Join industry experts to explore how AI can transform workflows to help sponsors and CROs better manage data while maintaining speed, quality and compliance. Register now.
|
|
Today’s Big NewsJan 29, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now.
|
|
| By Gabrielle Masson A judge has sided with Aurion Biotech in a lawsuit brought by investor Alcon Research that aimed to stop the biotech's planned IPO. |
|
|
|
By Nick Paul Taylor I-Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline reprioritization. |
By James Waldron The FDA’s move to lift the hold on Zentalis Pharmaceuticals’ sole clinical-stage drug may have been good news for the biotech—but it’s been bad news for some of its staff. The company is now laying off 40% of its employees as it gears up for registrational studies in ovarian cancer. |
Sponsored by Salesforce Drug development and commercialization leads to tremendous advances in medicine and improvements to everyday life, but it often comes at a cost. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now.
|
|
By James Waldron Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the data close to its chest for now. |
By James Waldron Two weeks after its bacteria-based therapy scored a phase 2 lung cancer win, OS Therapies has penned a deal that will secure the full intellectual property rights to the drug along with a pair of additional clinical-stage therapies. |
By Darren Incorvaia Decentralized clinical trials, which allow patients to participate locally or remotely using digital tech, end up enrolling more diverse populations than traditional trials, according to new data from the Tufts Center for the Study of Drug Development’s PACT consortium. |
By Darren Incorvaia Demand slipped for several large contract research organizations last year, and a new report from William Blair suggests these firms shouldn’t expect much improvement in 2025. |
By Dave Muoio,Noah Tong Though the administration said Tuesday that Medicaid would not be caught up in a hold on federal program payments, industry groups and legislators say that portals in all 50 states are down. This comes as other questions remain on whether Monday's ambiguous memo will interrupt clinical research, community health centers, suicide prevention, state infectious disease surveillance and other government-backed efforts. |
By Kevin Dunleavy So far this month, companies in the biopharma industry have raised prices on more than 930 products but the increases have largely been modest, averaging 4%. |
By Dave Muoio A Tuesday night order pulls federal funds from healthcare providers treating trans those under 19 with what the Trump administration refers to as "chemical and surgical mutilation." The order also pulls coverage of the services from government insurers and signals broad law enforcement support for prohibitory state laws. |
By Conor Hale The new 510(k) clearance expands the portfolio of the company’s Zoom aspiration system to add the Zoom 88, with its 0.088 inch-wide opening. |
Fierce podcastsDon’t miss an episode |
| | While major payers skipped out on this year’s event, health tech companies, health systems and insurtechs all made appearances to share their latest updates with investors. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now.
|
|
| Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
